Sanofi Genzyme's Sibold On Investing In Blood Disorders And Fending Off Rivals
Sibold talked to Scrip about launching the blood clotting disorder drug Cablivi and finding room in a competitive hemophilia market.
You may also be interested in...
In CEO Paul Hudson's first earnings call at the company's helm, he said he has big goals for driving growth but a deeper strategic update will be outlined to investors on Dec. 10 in Cambridge, Mass.
Hours after getting the nod from the FDA for Cablivi, the French drugmaker has had an R&D pipeline overhaul and says it could potentially submit nine new medicines and 25 additional indications to regulatory authorities from 2019 to 2022.
Hemlibra was approved to prevent or reduce bleeding in adults and children with hemophilia A without factor VIII inhibitors, a significantly larger patient population than its current indication in patients with factor VIII inhibitors.